Skip to content

PENGUIN-trial: pancreatitis, endoscopic transgastric versus primary necrosectomy in patients with infected necrosis. A randomised controlled multicenter observer-blinded trial

PENGUIN-trial: pancreatitis, endoscopic transgastric versus primary necrosectomy in patients with infected necrosis. A randomised controlled multicenter observer-blinded trial - PENGUIN-trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON33864
Enrollment
20
Registered
2007-04-12
Start date
2008-08-20
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection of pancreas pancreatitis

Interventions

Patients will be randomly assigned to receive either endoscopic transgastric necrosectomy or necrosectomy by laparotomy and continuous postoperative lavage.

Sponsors

Sint Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age equal to or above 18 years - Pancreatic necrosis or peripancreatic necrosis detected on CECT. - Patients in whom a decision for surgical intervention has been made because of (suspected) infected (peri-)pancreatic necrosis - Safe access route for endoscopic transgastric necrosectomy - Written informed consent

Exclusion criteria

Exclusion criteria: - Participation in another intervention trial that would interfere with the intervention and outcome of this study - Previous surgical necrosectomy for (suspected) infected pancreatic necrosis, Including procedures performed in referring hospitals. Previous percutaneous or transgastric drainage is allowed. - Previous exploratory laparotomy for acute abdomen and diagnosis of pancreatitis during laparotomy - Acute flare-up of chronic pancreatitis - Bleeding, abdominal compartment syndrome or perforation of a visceral organ as indication for intervention - Post-abdominal surgery necrotizing pancreatitis

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the total pro-inflammatory response as measured by the maximum increase in level of serum cytokine IL-6 in the period between start of the first necrosectomy and five hours thereafter.

Secondary

MeasureTime frame
Secondary endpoints are complications (bleeding, perforation, pancreatic fistula, pancreatic pseudocyst requiring intervention, pancreatic abscess requiring intervention, biliary strictures, incisional hernia requiring re-intervention and pancreatic insufficiency) and mortality, total number of interventions, hospital and intensive care stay.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)